{"id":107537,"date":"2019-05-04T00:00:50","date_gmt":"2019-05-17T09:17:09","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/107537\/"},"modified":"2019-05-17T17:17:32","modified_gmt":"2019-05-17T09:17:32","slug":"0e2e4b620f","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/107537\/","title":{"rendered":"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e: CAR-T\u7ec6\u80de\u6cbb\u7597\u7814\u53d1\u53ca\u751f\u4ea7\u5de5\u827a\u56fd\u9645\u8bba\u575b"},"content":{"rendered":"
\n

2019\u5e744\u670816-17\u65e5\uff0cCAR-T\u7ec6\u80de\u6cbb\u7597\u7814\u53d1\u53ca\u751f\u4ea7\u5de5\u827a\u8bba\u575b\u66a8\u4e9a\u592a\u836f\u7269\u7814\u53d1\u9886\u8896\u5cf0\u4f1a2019\u5728\u5386\u7ecf\u4e00\u4e2a\u4e16\u7eaa\u7684\u65f6\u5149\u66f4\u8fed\uff0c\u6108\u52a0\u96cd\u5bb9\u534e\u7f8e\uff0c\u5c3d\u663e\u56fd\u9645\u98ce\u8303\u7684\u4e0a\u6d77\u745e\u91d1\u6d32\u9645\u9152\u5e97\u6210\u529f\u4e3e\u529e\u3002<\/span><\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:
<\/p>\n

\u65e9\u5e74\uff0c\u6bdb\u6cfd\u4e1c\u4e3b\u5e2d\uff0c\u5468\u6069\u6765\u603b\u7406\u7b49\u56fd\u5bb6\u9886\u5bfc\u4eba\u4ee5\u53ca\u5176\u4ed6\u7684\u56fd\u5bb6\u653f\u5e9c\u9ad8\u5c42\u90fd\u66fe\u5728\u6b64\u4e0b\u69bb\u3002\u89e3\u653e\u6218\u4e89\u65f6\u671f\uff0c\u8fd9\u91cc\u66fe\u662f\u4e2d\u56fd\u5171\u4ea7\u515a\u5728\u4e0a\u6d77\u7684\u7b2c\u4e00\u4e2a\u91cd\u8981\u519b\u4e8b\u6307\u6325\u90e8\u3002<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:
<\/p>\n


<\/p>\n

\u53d1\u8a00\u5609\u5bbe\u7cbe\u5f69\u56de\u987e\uff1a<\/strong><\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Leaders Fireside Chat: Revolution and Strengthening Collaboration for Future CAR-T Therapies<\/strong><\/span>
Moderator:
Dr. Mickey Koh<\/strong>
Director-Stem Transplantation, Consultant Haematologist\/Hon Senior Lecturer, <\/span>St George\u2019s Hospital and Medical School, London, U.K<\/strong>
Panelists:
Dr. Renier Brentjens<\/strong>
Director, ular Therapeutics, Associate Chair, Junior Faculty Development, Department of Medicine,Memorial Sloan-Kettering Cancer Center<\/strong>
D<\/strong>r. Cheng Liu<\/strong><\/span><\/p>\n

Founder and Chief Executive Officer, <\/span><\/span>Eureka Therapeutics<\/strong><\/span><\/p>\n

Dr. Eric Smith<\/strong>
<\/span><\/p>\n

Director Translational Development ular Therapeutics Center; Assistant Attending, Myeloma Service,Memorial Sloan-Kettering Cancer Center<\/strong>
Dr. Delara Motlagh
<\/strong>Vice President, Therapy Technologies, <\/span><\/span>Terumo BCT<\/strong><\/span><\/p>\n

Dr. John Connolly<\/strong>
<\/span><\/p>\n

Chief Scientific Officer, <\/span>Tessa Therapeutics Ltd<\/strong>
Dr. Richard Wang<\/strong>
Chief Executive Officer, <\/span>Fosun Kite Biotechnology<\/strong><\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Panel Discussion: Strengthening Collaboration for Development & Commercialization CAR-T Therapy in China<\/strong><\/span>
Moderator:
Dr. Hermann Bohnenkamp<\/strong>
Vice President, Business Development APAC, <\/span>Miltenyi Biotec<\/strong>
Panelists:
Mr. Tony Liu<\/strong>
Chief Executive Officer & Chief Financial Officer, <\/span>ular Biomedicine Group<\/strong>
Dr. Lei Yu<\/strong>
Chief Executive Officer, <\/span>UniCAR-Therapy Bio-Medicine Technology<\/strong>
Dr. James Li<\/strong>
Chief Executive Officer, <\/span>JW Therapeutics<\/strong>
Dr. Lin Yang<\/strong>
Chief Executive Officer, <\/span>PersonGen BioTherapeutics ( Suzhou )<\/strong>
Dr. Daniel Song<\/strong>
Vice President, <\/span>HRAIN Biotechnology<\/strong>
Dr. Wendy Li<\/strong>
Chief Medical Officer, <\/span>Exuma Biotechnology SEZC<\/strong><\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Panel Discussion: Key Considerations of Development Next Generation of CAR-TCR Therapy in China<\/strong><\/span><\/p>\n

Moderator:
<\/span>Dr. Jijun Yuan
<\/strong>Chief Executive Officer, <\/span>Shanghai Genbase Biotechnology
<\/strong>Panelists:
Dr. Ting He
<\/strong><\/span><\/p>\n

Chief Executive Officer, <\/span>ImmunoChina Pharmaceuticals<\/strong><\/span>
<\/p>\n

Dr. Jianqiang Li
<\/strong><\/span><\/p>\n

Chairman and Chief Scientific Officer, <\/span>Senlang Bio<\/strong><\/span><\/p>\n

Dr. Qihong Sun<\/strong>Vice President & Chief Medical Officer, <\/span>Asclepius Technology Company Group<\/strong><\/span><\/strong><\/span><\/p>\n

Dr. Li Zhou
<\/strong>Vice President of Therapy and Antibody Research, <\/span>Luye Boston R&D Center<\/strong><\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Renier Brentjens<\/strong>
Director, ular Therapeutics, Associate Chair, Junior Faculty Development, Department of Medicine,Memorial Sloan-Kettering Cancer Center<\/strong><\/span><\/p>\n

Keynote\uff1aClinical Development of CAR T Therapy & Next Generation CAR T cells<\/strong><\/span><\/p>\n

– Define the concept of CAR T cell therapy for cancer
– <\/span><\/span>Summarize clinical outcomes of CAR T cell trials<\/span><\/p>\n

– <\/span><\/span>Recognize barriers to CAR T therapy of cancer and highlight novel<\/span> <\/span>approaches to overcome these barriers<\/span><\/p>\n

– <\/span><\/span>Recognize novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armored CAR T cell designs may bridge the gap from liquid to solid tumors<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Eric Smith<\/span><\/strong>
Director of Translational Development – ular Therapeutics Center\uff0cMemorial Sloan-Kettering Cancer Center<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Advances in CAR T cell therapy for Multiple Myeloma<\/span><\/strong>
– BCMA targeted CAR T cell therapy has dramatic efficacy in heavily pretreated patient population, but relapse is common
– Potential causes of relapse: Antigen escape, anti-CAR immunity, lack of CAR T cell expansion\/functional persistence
– Addressing relapse: Targeting additional antigens, human CAR, optimized CAR design<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Mickey Koh<\/span><\/strong>
Director-Stem Transplantation, Consultant Haematologist\/Hon Senior Lecturer, <\/span>St George\u2019s Hospital and Medical School<\/strong>
Medical Director, Therapy Facility, Division Director and Consultant Haematologist, <\/span>Health Sciences Authority, Singapore<\/strong><\/span><\/p>\n

Keynote<\/span>\uff1a Based Therapies: Key Considerations for Clinicians, Health Care Systems, International Societies and Regulatory Authorities<\/span><\/span><\/strong><\/p>\n

– Landscape of cell therapy in Asia
– Initiative for therapy in Singapore
– therapy Trials in Singapore and Asia
– Regulatory convergence
– Unproven therapies<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Pei-Hua (Peggy) Lu<\/span><\/strong>
Medical Executive President, <\/span>Lu Daopei Hospital, Beijing,<\/strong> <\/span>Lu Daopei Institute of Hematology<\/strong><\/span><\/p>\n

Keynote\uff1aCD19 CAR-T Treatment for R\/R B-cell ALL<\/span>
– Summarize the development of CAR T cell therapy for hematological malignancies
– Display clinical outcomes of CD19 CAR T treatment in R\/R B-cell ALL including a large cohort of high-risk subgroups in our center
– Compare the effects of CD19+CD22 to CD 19 CAR T for R\/R B-cell ALL patients
– Explain the benefits from bridging into transplant after CAR-T for B-cell ALL patients<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. John Connolly<\/span><\/strong>
Senior Principal Investigator and Director for Translational Immunology, Institute of Molecular and ular Biology (IMCB), <\/span>A*STAR Singapore<\/strong>; Chief Scientific Officer, <\/span>Tessa Therapeutics Ltd<\/strong><\/span><\/p>\n

Keynote\uff1aVirus Specific T s as Platform for Solid Tumor Immunotherapy<\/span><\/strong>
The ability to simultaneously monitor changes in multiple immune parameters holds great discriminatory and instructive power for the purpose of biomarker validation and mechanistic target discovery. In the case of Virus Specific T cell therapy for solid tumors, an examination of the systemic, cellular and local immune environment during the course of treatment has yielded a series of predictive biomarkers correlating with immunogenicity, response to therapy and overall survival on trial. An analysis of antigen specific T-cells have identified anti-viral responses with positive prognostic value. Differences in the immunosuppressive state of the patient\u2019s activated regulatory T-cells (Tregs) and the expansion or contraction of the myeloid-derived suppressor cell (MDSC) compartment, point to a mechanism of action for the therapy.<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Cheng Liu<\/span><\/strong>
Founder and Chief Executive Officer, <\/span>Eureka Therapeutics<\/strong><\/span><\/p>\n

Keynote<\/span>\uff1a<\/span><\/span><\/strong>Towards safer, more effective and persistent T-cell therapies: Development of antibody-TCR (AbTCR) expressing T cells against solid and hematological malignancies<\/span><\/p>\n

– Major barriers of current CAR-T – CRS and neurotoxicity risks
– ARTEMIS AbTCR T-cell Receptor Platform intro
– Safety validation of ARTEMIS platform in CD19+ NHL
– Eureka built a versatile structure to go after solid tumor by using a TCRm antibody on ARTEMIS platform
– Safety and efficacy validation in AFP+ HCC is achieved
– Future directions to expand the ARTEMIS platform<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Zonghai Li<\/span><\/strong>
Founder, CEO and CSO, <\/span>CARSgen Therapeutics<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Development of next-generation of CAR T cells<\/span><\/span><\/strong>
– Problems of current CAR-T cell therapeutics in clinic
– Innovative safety switch for CAR-T cells
– Next-generation of CAR-T cells with increased antitumor activities<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. James Li<\/span><\/strong>
Chief Executive Officer and Co-Founder, <\/span>JW Therapeutics<\/strong><\/span><\/p>\n

Keynote<\/span>\uff1a<\/span><\/strong>Revolution of CAR-T Therapies and Innovation in China<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Wei (William) Cao<\/span><\/strong>
Founder, Chairman and CEO, <\/span>Gracell Biotechnologies<\/strong><\/span><\/p>\n

Keynote\uff1aFasT CAR-T \u2013 Breakthrough Technology For Hematological Malignancies<\/span><\/strong><\/span>
Chimeric antigen receptor T cell (CAR-T) therapy has been a success in treating acute lymphoblastic leukemia (ALL) and non-Hodgkin\u2019s lymphoma (NHL). However, the therapeutic potential can still be further improved. In addition, long manufacturing time and high cost of CAR-T product limit the wider applications of CAR-T therapy. We have developed a new manufacturing platform, FasT CAR-T, in that the manufacturing time is shortened to one day (plus 7 days for releasing tests per regulatory requirement) as compared to the conventional CAR-T manufacturing time of 9-14 days plus 7 days. Hence the FasT CAR-T\u2019s vein-to-vein time is shortened by an average of 12 days, which is critical for patients with rapidly progressing disease. More importantly, CD19-directed FasT CAR-T has been shown to have superior expansion capability, younger and less exhausted phenotype, and higher potency in eliminating B-ALL and NHL both in vitro and in vivo. First-in-human clinical study is ongoing and the early results show that FasT CAR-T is safe, and significantly more potent than the conventionally-manufactured CAR-T.<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Ting He
<\/strong>Chief Executive Officer, <\/span>ImmunoChina Pharmaceuticals<\/strong><\/span><\/p>\n

Keynote\uff1aDevelopment of CAR-T Targeting Hematological Malignancies<\/span><\/strong><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Lin Yang<\/strong>
Chief Executive Officer, <\/span>PersonGen BioTherapeutics ( Suzhou )<\/strong><\/span><\/p>\n

Keynote\uff1aAutomated Manufacturing of Chimeric Antigen Receptor T s<\/span><\/strong><\/span><\/p>\n

The chimeric antigen receptor gene-modified T cells (CAR-T cells) technology has been proven clinically successful since 2010, especially targeting CD19 molecules in the treatment of refractory, relapsed B cellderived malignancies in which the clinical efficacy has never been achieved by traditional tumor therapy strategies, and become the most attractive area in cancer immunotherapy. However, CAR-T cell technology has been experiencing huge challenges, including the expensive preparation and quality control costs for CAR-T cells and lacking clinically verified automated and closed technology. In another word, current mainstream technology hugely relies on highly skillful personnel that increases risk of contamination and production failure, and brings uncertainty for its industrialization. In this presentation, Dr. Yang will analyze the development trend based on his team\u2019s effort in this area, and summarize how applying automated platform to CAR-T cell manufacturing will prompt CAR-T cell technology industrialization and lead to clinical success.<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Jishuai Zhang<\/span><\/strong>
Chief Scientific Officer, <\/span>The Shenzhen Pregene Biopharma Company, Ltd<\/strong><\/span><\/p>\n

Keynote\uff1aThe development of CART targeting BCMA using the single domain antibody as the antigen recognition domain<\/span><\/strong>
– The introduction for single-domain antibodies
– The development and clinical effect of CART targeting BCMA using the single domain antibody as the antigen recognition domain.<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Xiao Lei<\/span><\/strong>
Chairman, Chief Scientific Officer, <\/span>Innovative ular Therapeutics<\/strong><\/span><\/p>\n

Keynote\uff1aThe preliminary results of the first-in-class dnPD1\u201cArmored\u201d CAR-T proof of concept clinical study in r\/r NHL patient<\/span>
– An introduction of the dominant negative PD1 platform technology
– The pre-clinical data of ICTCAR014
– Preliminary clinical data of ICTCAR014<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Yu Zhang<\/span><\/strong>
Co-Founder and Chief Executive Officer, <\/span>Aeon Therapeutics<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Key Considerations in Developing Anti-AFP (TCR-mimic) Artemis T product for HCC in China<\/span><\/span><\/strong><\/p>\n

– Major Challenges for CAR-T therapy in solid tumors, especially in HCC
– Developing investigator-initiated clinical study of using anti-AFP Artemis T cell to treat patients with HCC in China
– Key considerations in translating and developing anti-AFP Artemis T cell product for IND and commercialization in China<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Jianqiang Li<\/span><\/strong>
Chairman and Chief Scientific Officer, <\/span>Senlang Bio<\/strong><\/span><\/p>\n

Keynote\uff1aDevelopment of Combined CAR-T s in Therapy against Solid Tumors<\/span><\/strong><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Qihong Sun<\/span><\/strong>
Vice President & Chief Medical Officer, <\/span>Asclepius Technology Company Group<\/strong><\/span><\/p>\n

Keynote\uff1aIn Situ Vaccination of Monoclonal CAR-NK s Activates Systemic Immunity against Tumors<\/span>
This presentation will be introduced from three aspects: Seamless large scale production of CAR-NK, Activation of systemic immunity, and in Situ vaccination to treat solid tumors. We has been focused on developing innovative \u201coff-the-shelf\u201d CAR-NK cell drugs for cancer immunotherapy. The R&D team at ATCG, led by Drs. Huashun Li has been based on natural killer cell line NK-92 as a platform to develop over 15 CAR stably expressing NK cell lines (CAR-NK) to treat different types of solid tumors. The preliminary clinical research studies have shown that ATCG427 CAR-NK therapy yields a remarkable response rate and partly persistent remission in the treatment of over 80% solid tumors including but not limited to breast cancer, lung cancer, renal cancer, and pancreatic cancer. ATCG has been well positioned in the fast growing tumor immunotherapy field with the proprietary CAR-NK technology.<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Jie (Kathryn) Liu<\/span><\/strong>
Principal Scientist, <\/span>Fosun Kite Biotechnology<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Translational Data Supporting Development of Yescarta\u00ae and Mechanisms of Resistance to CD19 CAR T Therapy<\/span><\/span><\/strong><\/p>\n


<\/p>\n

\u65b0\u6280\u672f<\/span><\/strong>\u3001<\/span><\/strong>\u65b0\u5e73\u53f0\u7684\u5e94\u7528\u4ecb\u7ecd<\/span><\/strong><\/span><\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Hermann Bohnenkamp<\/strong>
Vice President, Business Development APAC, <\/span>Miltenyi Biotec<\/strong><\/span><\/p>\n

Keynote\uff1aTowards Commercialization \u2013 Accomplish the Challenges of Autologous and Gene Therapies<\/span><\/strong>
– Control strategies for cell and gene therapies
– Considerations of a fully automated cell manufacturing process
– Process transfer and decentralized manufacturing strategies of CAR T cells<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Delara Motlagh<\/strong>
Vice President, Therapy Technologies, <\/span>Terumo BCT<\/strong><\/span><\/p>\n

Keynote\uff1aFrom Compelling to Propelling: The Drive to Accelerate and Gene Therapies to Market<\/span><\/strong>– Global progress and momentum in the cell and gene therapy market
– Needs and challenges for various stakeholders on the path to commercialization
– Collaboration to drive standardization in the industry<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Philip G. Vanek<\/strong>
General Manager, and Gene Therapy Strategy, <\/span>GE Healthcare<\/strong><\/span><\/p>\n

Keynote\uff1aIndustrializing & Gene Therapies: Managing Complexity Across the Ecosystem<\/span><\/strong><\/p>\n

– and gene therapies hold tremendous clinical promise but are complex and costly
– Dealing with patient heterogeneity and treatment histories complicates manufacturing
– The supply chain has many steps, but new technologies are emerging to improve efficacy and manufacturing efficiency
– Data collection, analytics, and automation will help scale manufacturing of cell and gene therapies<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Mr. Shen Liang<\/span><\/strong>
Manager of Platform Development Specialists, <\/span>Sartorius Stedim (Shanghai) Trading Co. Ltd<\/strong><\/span><\/p>\n

Keynote\uff1aPlatform Technology to Scale Up CAR-T to Commercial Manufacturing<\/span><\/strong>
– QbD implementation in CAR-T on process development and process characterization
– Single use technologies for closure system and risk mitigation
– Single use technologies quality risk management
– Technologies for data management, in-process control and release testing<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Neil Kayal<\/span><\/strong>
Global Bio-Pharma Manager – and Gene Therapy Commercialization, <\/span>Beckman Coulter<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Evolution in the Manufacturing of ular Therapies – Lessons Learned and Current Solutions<\/span><\/strong>
Immunotherapy is a powerful treatment that harnesses the body\u2019s immune system in the fight against cancer. With optimized cell therapy, the result is an expanded population of T cells primed to recognize and eradicate malignant tumor cells that would otherwise escape immune detection.<\/span><\/p>\n

– Commercialization of manufacturing- preparing a CAR Garage,lessons learned and how does it impact the patient
– Automated functional testing- fully integrated unit operations taking the art out of science!<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr Jacqueline Barry<\/span><\/strong>
Chief Clinical Officer, <\/span>The & Gene Therapy Catapult<\/strong><\/span><\/p>\n

Keynote\uff1aCAR-T Approval and Adoption Considerations<\/span><\/strong><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. James Brady<\/span><\/strong>
Vice President of Technical Applications and Customer Support\uff0cMaxCyte<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Advancing ular Therapies with a cGMP-Compliant Non-viral Engineering Platform<\/span><\/strong>
The field of cellular therapy has advanced rapidly in recent years due to the emergence of precision tools for genome modification. Chimeric antigen receptors and CRISPR\/Cas9 gene editing reagents are enabling researchers and clinicians to target T cells and NK cells to diseased tissues and to engineer phenotypic changes that were unimagined only a few years ago. Although cell and gene therapies have been approved by the FDA, it remains imperative that researchers consider early in development whether their cell engineering method meets the stringent demands of clinical use – – namely the ability to safely and reproducibly modify human primary or stem cells with high efficiency, low cytotoxicity, and at the scale required to treat patients. MaxCyte\u2019s ExPERT platform, a non-viral cell engineering technology designed to fulfill these demands, has an established record of rapidly advancing cell- and gene-based therapies to the clinic. This presentation will highlight the high efficiency, high viability, fully scalable engineering of a variety of primary hematopoietic cells, stem cells and hiPSCs as well as their real-world application in pre-clinical disease modeling and IND-enabling studies for the therapeutic correction of monogenic disease mutations such as Xlinked chronic granulomatous disease (X-CGD) and sickle cell disease (SCD).<\/span><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Mr. Max Wang<\/span><\/strong>
Director, China Operations, PMP, <\/span>Werum IT Solutions<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>A Practical Strategy for a & Gene Digitized Supply Chain<\/span><\/span><\/strong><\/p>\n

The anticipated explosive growth and critical supply chain requirements of the & Gene sector cannot be fully supported by traditional pharmaceutical and bio-tech solutions. There is enough learning coming from the commercial pioneers to paint a practical vision for the digitized supply chain
– Key solution learnings from the first wave of sector commercialization
– The impediments to scale solved by digitization
– Identification of key components of comprehensive solution architecture
– Leveraging commercial solutions vs filling the white spaces
– Translating the strategy to successful solution deployments<\/span>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Dr. Kai Zhu<\/span><\/strong>
Vice President and Co-Founder, <\/span>Help Stem Innovation Ltd<\/strong><\/span><\/p>\n

Keynote\uff1a<\/span>Next Generation Drug Screening based on Novel iPSC-derived Cardiomyocyte Platform<\/span><\/span><\/strong>
<\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Mr. Christopher Griffith<\/span><\/strong>
Partner, <\/span>Green, Griffith & Borg-Breen LLP<\/strong><\/span><\/p>\n

Keynote\uff1aKey C<\/span><\/strong>onsiderations<\/span><\/strong> <\/span>of US IP Law relating to Pharma and Biologics<\/span><\/strong><\/p>\n


<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

Panel Discussion:<\/span> <\/span><\/span>Key Considerations of IP Patent Relating to Pharma & Biologicals Development<\/span><\/strong>
Moderator:
Mr. Christopher Griffith<\/strong>
Partner, <\/span>Green, Griffith & Borg-Breen LLP<\/strong>
Panelists:
Mr. Alex Liu
<\/strong>Head of Intellectual Property Rights, <\/span>Bayer (China) Limited<\/strong>
Mr. Kent Yang
<\/strong>Head of Patents China, <\/span>Novartis Pharmaceuticals (China)
Mr. Weibin Wang
<\/strong>Senior Partner, <\/span>Shanghai Beshining Law Office<\/strong><\/span><\/p>\n

Ms. Caihui Li
<\/strong><\/strong>IP Director, <\/span><\/span>3S Pharmaceutical Group<\/strong><\/strong><\/span><\/p>\n


<\/p>\n

\u805a\u7cbe\u4f1a\u795e\u7684\u542c\u4f17<\/strong><\/span><\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n


<\/p>\n

\u7cbe\u5f69\u4e92\u52a8\u63d0\u95ee\u73af\u8282<\/strong><\/span><\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:
<\/p>\n


<\/p>\n

\u4ea4\u6d41\u53ca\u5c55\u53f0\u8bbf\u95ee\u73af\u8282\uff1a<\/strong><\/span><\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

\u8bc6\u522b\u5fae\u4fe1\u4e8c\u7ef4\u7801\uff0c\u6dfb\u52a0\u5c0f\u7f16\uff0c\u7b26\u5408\u6761\u4ef6\u8005\u5373\u53ef\u52a0\u5165\u751f\u7269\u5236\u54c1\u5fae\u4fe1\u7fa4\uff01<\/strong><\/p>\n

\n
\n

\u8bf7\u6ce8\u660e\uff1a\u59d3\u540d+\u7814\u7a76\u65b9\u5411\uff01<\/strong><\/span><\/p>\n

\n
\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:
<\/p>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n
\n
\n
\u7248<\/section>\n<\/section>\n
\n
\u6743<\/section>\n<\/section>\n
\n
\u58f0<\/section>\n<\/section>\n
\n
\u660e<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u672c\u516c\u4f17\u53f7\u6240\u6709\u8f6c\u8f7d\u6587\u7ae0\u7cfb\u51fa\u4e8e\u4f20\u9012\u66f4\u591a\u4fe1\u606f\u4e4b\u76ee\u7684\uff0c\u4e14\u660e\u786e\u6ce8\u660e\u6765\u6e90\u548c\u4f5c\u8005\uff0c\u4e0d\u5e0c\u671b\u88ab\u8f6c\u8f7d\u7684\u5a92\u4f53\u6216\u4e2a\u4eba\u53ef\u4e0e\u6211\u4eec\u8054\u7cfb(cbplib@163.com)\uff0c\u6211\u4eec\u5c06\u7acb\u5373\u8fdb\u884c\u5220\u9664\u5904\u7406\u3002\u6240\u6709\u6587\u7ae0\u4ec5\u4ee3\u8868\u4f5c\u8005\u89c2\u70b9\uff0c\u4e0d\u4ee3\u8868\u672c\u7ad9\u7acb\u573a\u3002<\/span>
<\/p>\n

\"\u7cbe\u5f69\u4f1a\u8bae\u56de\u987e:<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

2019\u5e744\u670816-17\u65e5\uff0cCAR-T\u7ec6\u80de\u6cbb\u7597\u7814\u53d1\u53ca\u751f\u4ea7\u5de5\u827a\u8bba\u575b\u66a8\u4e9a\u592a\u836f\u7269\u7814\u53d1\u9886\u8896\u5cf0\u4f1a2019\u5728\u5386\u7ecf\u4e00\u4e2a\u4e16\u7eaa\u7684 […]<\/p>\n","protected":false},"author":1,"featured_media":107538,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/107537"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=107537"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/107537\/revisions"}],"predecessor-version":[{"id":107580,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/107537\/revisions\/107580"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/107538"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=107537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=107537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=107537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}